PepTalk 2017
PepTalk 2017
Archived Content

Pipeline 3 Header 

Ninth Annual
Antibodies for the 21st Century
Engineering the Next Generation
January 23-24, 2013 


Day 1| Day 2 | Download Pipeline 3 Brochure 


7:15 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee



8:45 Chairperson’s Remarks

Vaughn Smider, M.D., Ph.D., Assistant Professor, Molecular Biology, The Scripps Research Institute

8:50 Arrayed IgG Libraries: GPCR Antibody Discovery Directly on the Cell Surface

Cory BentleyCory Bentley, Ph.D., Senior Scientist, Fabrus LLC - Biography 

Antibody discovery typically requires purified protein to be used for immunization or selection of a display based library.  We have generated a 10,000 member spatially addressed IgG library with a single synthetic germline antibody per microtiter well.  This library was directly screened against target cells by high-throughput flow cytometry to obtain specific hits against GPCR antigens in their native cellular context.  This format could pave the way to antibody discovery against previously intractable targets expressed only in cells.

9:20 3CARD: Ultra-Fast Single Round Phage and Yeast Display Antibody Library Screening Using Coupled Enzyme Reactions

Harold KolmarHarald Kolmar, Ph.D., Professor and Head, Biochemistry, Technical University Darmstadt - Biography 

In collaboration with EMD-Serono we have developed a generally applicable method that allows one to obtain target binding antibodies from a single round of large library screening. We show that selective biotinylation of phage particles and yeast cells displaying a binder to any given target can be achieved via application of a coupled enzyme reaction on the surface of the target-binding replicating entity. The method, termed 3CARD was applied to the successful single-round screening of phage and yeast surface display libraries.


The Linker is Everything: Design and Enhancement of an Avid IgG Binding Protein for mAb Mediated Theranostics -- Poster #B302

Kendra N. Avery, Ph.D., Postdoctoral Research Fellow, Department of Molecular Medicine, City of Hope Beckman Research Institute

10:05 Coffee Break in the Exhibit Hall with Poster Awards


Next-Generation Technologies 

10:45 Automating HTP Antibody Engineering and Small Scale Production

Christoph Freiberg, Ph.D., Senior Scientist, Cell and Protein Sciences, Bayer HealthCare - Biography 

We have implemented an automated HT biologics screening and an automated transient mg-scale antibody production process for the discovery, optimization and production of monoclonal antibody leads. We describe a typical workflow from Fab screening via IgG reformatting to IgG research material production with focus on data management supported by Genedata’s Biologics software solution.

11:15 When Evolution Meets Technology – Nanobodies: A Robust Platform for the Generation of Innovative Biotherapeutics

Andreas MenradAndreas Menrad, Ph.D., Chief Scientific Officer, Ablynx - Biography 

Nanobodies are antibody-derived therapeutic proteins containing the unique structural and functional properties of naturally occurring heavy-chain antibodies. The modularity of this technology allows for control over valency, in vivo half life and effector function.  Furthermore, Nanobodies provide a robust platform for both single- and multispecific compounds.  Examples spanning pre-clinical up to Phase II will be used to illustrate the ease with which these different goals can be met without compromising manufacturability.

11:45 High-Throughput Generation of Monoclonal and Antigen-Specific Rabbit Antibodies from Blood Using B-Cell Cloning and B-Cell PCR

Stefan Seeber, Ph.D., Principal Scientist, Molecule and Cell Line Development, Roche Diagnostics GmbH - Biography 

We have developed a new two-step technology involving the isolation and cloning of single B cells from rabbit blood samples after immunization, screening of the B-cell supernatants, followed by automated and high-fidelity B cell PCR of the antibody coding sequences. The antibodies can then directly be sequenced and expressed or genetically engineered to create chimeric antibodies as well as bispecific antibodies, antibody fragments and other scaffolds. An example will be presented of generating antibodies against a human interleukine receptor.

12:15 pm Close of Morning Session

SDIX12:30 Luncheon Presentation: Multipass Membrane Protein Monoclonal Antibodies by DNA Immunization and High Throughput Flow Cytometry Screening 
 James W. Stave, Ph.D., Senior Research Fellow, SDIXMultipass transmembrane proteins like GPCRs and ion channels, are important targets for therapeutic monoclonal antibody (mab) discovery. Small numbers of extracellular amino acids, homology and post-translational modifications make these targets challenging.  Panels of mabs were isolated for CXCR4, ADORA2A, and CD20. Mabs generated using this approach are unique, bind cells with diverse epitope specificities, and exhibit functional activity as good or better than existing benchmark therapeutic antibodies.

1:30 End of Conference

Day 1| Day 2 | Download Pipeline 3 Brochure